Inhalation-Based Nanoparticle Drug Delivery Targeting the Diseased Lower Airways in IPF

Abstract

Idiopathic pulmonary fibrosis (IPF) is a fatal disease initiated in the lower airways that disrupts the lung's functional architecture. Current therapeutics—pirfenidone and nintedanib—slow progression but cannot halt or reverse fibrosis. Inhaled nanomedicine offers a promising alternative by delivering mechanism-modifying drugs directly to the diseased regions, maximizing therapeutic effects while minimizing systemic side effects.

This review examines the anatomical and biological barriers specific to fibrotic lungs, surveys inhaled therapeutic modalities (small molecules, antibodies, peptides, nucleic acids) and nanocarrier platforms (exosomes, dendrimers, lipid/polymer nanoparticles), and discusses strategies for improving formulations toward clinical translation.

Introduction

Chronic airway diseases—including idiopathic pulmonary fibrosis (IPF), COPD, and allergic asthma—collectively constitute a major global health challenge. Although their etiologies differ, all initiate in the lower airways and result in remodeling of normal airway architecture. IPF is a non-resolving interstitial lung disease characterized by progressive scarring (fibrosis) that replaces healthy lung tissue with dense, stiff collagen, ultimately leading to respiratory failure.

The only FDA-approved therapies—pirfenidone and nintedanib—slow the decline in lung function but cannot stop or reverse fibrosis. Both are taken orally, resulting in systemic exposure that causes significant gastrointestinal and hepatic side effects, leading many patients to discontinue treatment. The median survival after IPF diagnosis remains just 3–5 years.

Delivering drugs directly to the lungs via inhalation could concentrate therapeutic agents where they are needed most—in the fibrotic lower airways—while reducing systemic toxicity. However, the lungs' sophisticated defense systems and the structural changes caused by fibrosis itself create formidable barriers to effective inhaled drug delivery. Nanoparticle-based carriers offer strategies to overcome these barriers.

Major Challenges for Inhalable Nanomedicine

Region-Specific Clearance Mechanisms

The respiratory tract has evolved multiple defense layers to keep foreign particles out. These barriers operate differently in the upper conducting airways versus the delicate gas-exchange region of the lower airways.

Mucociliary Escalator

In the conducting airways (trachea to bronchioles), a continuous mucus blanket traps inhaled particles. Coordinated beating of cilia moves this mucus upward at ~5 mm/min, clearing trapped particles within hours. Particles must either penetrate through mucus to reach underlying cells or be designed to resist clearance.

Alveolar Macrophage Clearance

In the alveolar region, resident macrophages rapidly engulf particles—especially those in the 0.5–5 µm range. This phagocytic clearance is the dominant removal mechanism in the lower airways, posing a major challenge for nanoparticle retention at the target site.

Aerodynamic Deposition

To reach the lower airways, particles need an aerodynamic diameter of 1–5 µm. Particles >5 µm deposit in the upper airways by impaction; particles <0.5 µm may be exhaled without depositing. The "nano-in-micro" strategy encapsulates nanoparticles within larger carrier particles that deposit in the target region, then release their nanoscale payload locally.

IPF-Specific Remodeling Barriers

What is IPF and why is it so hard to treat?

Idiopathic pulmonary fibrosis is essentially scarring of the lungs with no known cause ("idiopathic" means "of unknown origin"). Imagine the delicate, sponge-like tissue of your lungs being gradually replaced by tough scar tissue—like replacing a soft sponge with a block of concrete. This scarring makes it progressively harder to breathe. The only two approved drugs (pirfenidone and nintedanib) can slow the scarring process but cannot reverse damage already done. The median survival is just 3–5 years after diagnosis, similar to many aggressive cancers.

Lower Airway Injury Initiation: IPF begins with repetitive micro-injuries to the alveolar epithelium. Damaged type II alveolar cells fail to regenerate properly, instead producing aberrant differentiated intermediates (ADIs) marked by KRT5 and TP63, which drive pathological signaling cascades.

Dysregulated Mucociliary Clearance: In IPF, MUC5B is overexpressed (linked to a common risk-conferring promoter variant), creating thicker, more tenacious mucus that paradoxically both impairs normal clearance and traps therapeutic particles more aggressively.

Epithelial Remodeling: The normal thin alveolar epithelium is replaced by abnormal basal-like cells forming "honeycomb" cysts. These structural changes alter cell surface receptors and reduce the accessible surface area for drug absorption.

Basal Lamina Changes: The basement membrane thickens and changes composition, with increased collagen IV and laminin deposition creating an additional diffusion barrier between the airway lumen and target fibroblasts.

Fibroblastic Focus Heterogeneity: The key therapeutic targets—activated myofibroblasts within fibroblastic foci—are buried beneath the remodeled epithelium. These foci produce excessive ECM proteins (fibronectin, collagen I/III, tenascin-C) that are cross-linked by LOX enzymes, creating a dense, stiff matrix that physically impedes nanoparticle penetration.

Schematic of inhalable nanomedicine targeting lower airways in IPF — **Figure 1:** Schematic of inhalable nanomedicine targeting the lower airways in IPF. Left: nano-in-micro formulations, biogenic nanovesicles, and engineered dendritic carriers approach the alveolar region. Right: IPF disease progression from epithelial injury through ADI formation, EMT, fibroblastic focus development, and LOX-mediated ECM cross-linking.

Therapeutic Modalities for Inhalation

Four major classes of therapeutics are being explored for inhaled delivery to IPF lungs, each with distinct advantages and challenges for pulmonary administration.

Small Molecules

Advantages: Fast onset, well-established inhaler devices, low manufacturing cost. Pirfenidone and nintedanib are being reformulated for inhalation. Challenges: Limited selectivity for fibrotic tissue, primarily symptomatic benefit, risk of local irritation and systemic absorption through the thin alveolar membrane.

Antibodies

Advantages: Exceptional target specificity, durable pharmacological blockade, infrequent dosing potential. Anti-TGF-β, anti-IL-13, and anti-integrin antibodies show promise. Challenges: Protein denaturation during aerosolization, limited penetration to distal airways, viscosity and cold-chain requirements, immunogenicity risk.

Pep

Peptides

Advantages: Modular targeting of cell receptors and ECM components, rapid tissue access, scalable synthesis. ECM-targeting peptides can home to fibrotic regions. Challenges: Rapid proteolytic degradation in lung fluid, mucus and macrophage clearance, trade-offs in chemical modifications for stability.

Nucleic Acids

Advantages: Programmable target selection, ability to address "undruggable" targets (e.g., TGF-β signaling intermediates, collagen genes). siRNA, mRNA, and miRNA approaches in development. Challenges: Endosomal escape barrier, innate immune activation, nebulization/storage stability, complex CMC and regulatory requirements.

Four therapeutic modalities for inhalation in IPF — **Figure 2:** Therapeutic modalities for inhalation in IPF. Four-quadrant comparison of small molecules, antibodies, peptides, and nucleic acids with their respective advantages (blue arrows) and limitations (red arrows).

Nanoparticle Platforms for Pulmonary Delivery

Biogenic Nanovesicles (Exosomes)

Exosomes and other cell-derived vesicles (30–200 nm) offer innate biocompatibility and natural mucus-penetrating properties. They can carry mRNA, protein, and small molecule cargo. Surface coatings can enhance mucus penetration. However, challenges include low and variable yield, inefficient drug loading, batch heterogeneity, and risk of structural damage during aerosolization. Scale-up for clinical manufacturing remains a major hurdle.

What are exosomes? Exosomes are tiny bubbles (30–200 nm) that cells naturally release to communicate with each other. Researchers can harvest these vesicles and load them with drugs. Because they come from the body's own cells, the immune system tends to tolerate them well. For lung delivery, exosomes have a natural ability to penetrate mucus—but manufacturing them at clinical scale remains a significant bottleneck.

Dendritic Architectures

PAMAM dendrimers, dendron micelles, lipopeptides, and dendrimer-peptide conjugates offer precise size and valency control, multivalent targeting capability, high payload loading, and tunable release kinetics. They can incorporate imaging labels (IVIS/PET) for theranostic applications. Limitations include cationic surface-mediated mucoadhesion, cytotoxicity at high concentrations, aggregation risk, surfactant sensitivity, and multi-step synthesis complexity.

Lipid and Polymer Nanoparticles

Lipid nanoparticles (LNPs) and polymeric nanoparticles represent the most clinically advanced platforms. LNPs excel at nucleic acid delivery (as demonstrated by COVID-19 mRNA vaccines), while PLGA and chitosan-based polymeric NPs offer controlled release of small molecules and proteins. For IPF specifically, mucus-penetrating LNPs delivering dual mRNAs have shown reduced fibrosis in preclinical models. Inhaled liposomal pirfenidone outperformed oral pirfenidone in animal studies.

LNPs for IPF: building on COVID vaccine success

The same lipid nanoparticle technology that enabled COVID-19 mRNA vaccines is being adapted for IPF treatment. For lungs, the key innovation is formulating LNPs that can survive the physical stress of nebulization (being turned into a fine mist for inhalation) while retaining their ability to deliver RNA cargo to fibrotic cells. One promising approach uses "mucus-penetrating" LNPs with special surface coatings that slip through the thick mucus layer characteristic of IPF lungs.

Additional Scalable Platforms

Submicron emulsions, liposomes, and solid-lipid nanoparticles (SLNs) offer broad chemical compatibility, high payload loading, and flexibility for both liquid and dry-powder formulations. These platforms are compatible with multiple inhaler device types. Challenges include nebulization-induced aggregation, leakage risk, hygroscopicity management, residual solvent control, and cold-chain requirements for liquid formulations.

Aerosol Generation and Formulation Engineering

The choice of aerosol generation device critically impacts nanoparticle integrity and deposition pattern. Vibrating mesh nebulizers (e.g., Aerogen Solo) generate less shear stress than jet nebulizers, preserving LNP structure. Dry powder inhalers (DPIs) avoid aqueous instability entirely using spray-dried or spray-freeze-dried formulations with carrier particles (lactose, mannitol, leucine). The nano-in-micro approach—encapsulating nanoparticles within inhalation-sized microparticles—combines optimal aerodynamic deposition with nanoparticle-level cellular interactions.

Strategies for Clinical Translation

Key strategies include: excipient selection compatible with regulatory precedent (GRAS-listed materials), stability testing under real-world storage and nebulization conditions, bridging studies from rodent models to larger animals with human-relevant airway anatomy, device-formulation co-development, and establishment of quality control methods for particle size, drug loading, and aerodynamic performance.

The nano-in-micro strategy: There's a size paradox in inhaled drug delivery—nanoparticles (50–200 nm) are best for penetrating cells, but particles need to be much larger (1–5 µm) to deposit in the lower airways instead of being exhaled. The "nano-in-micro" approach solves this by packaging nanoparticles inside larger carrier particles made of materials like lactose or leucine. The micro-sized carrier deposits in the target region, then dissolves to release its nanoparticle payload for cellular-level drug delivery.

Nanoparticle platforms for pulmonary delivery - three tiers — **Figure 3:** Nanoparticle platforms for pulmonary delivery organized in three tiers. Top: Biogenic vesicles (exosomes). Middle: Dendritic architectures (PAMAM dendrimers, dendron micelles, lipopeptides). Bottom: Additional scalable platforms (emulsions, liposomes, polymeric NPs, SLNs). Each tier shows advantages and limitations.

Key Preclinical Studies

Formulation	Route	Stage	Disease Model	Key Finding
Mucus-penetrating LNPs (dual mRNAs)	Inhalation	Preclinical	Bleomycin IPF (mouse)	Reduced fibrosis with functional recovery and epithelial restoration
Polymeric NPs (siRNA targeting IL11)	Inhalation	Preclinical	Bleomycin IPF (mouse)	Antifibrotic effects with improved pulmonary function
ROS-responsive liposomes (dimethyl fumarate)	Inhalation	Preclinical	Fibrosis model (mouse)	Enhanced antifibrotic efficacy vs free drug; macrophage modulation
Liposomal NPs (verteporfin + pirfenidone)	Atomized inhalation	Preclinical	IPF models (mouse)	Improved lung function with reduced remodeling
Liposomes (Hsa-miR-30a-3p)	Inhalation	Preclinical	Bleomycin IPF (mouse)	Attenuated fibrosis with functional improvement
Surfactant-based pirfenidone nanovesicles	Inhalation	Preclinical	Bleomycin IPF (mouse)	Reduced collagen and α-SMA vs oral pirfenidone

Conclusions and Future Directions

Inhaled nanomedicine offers a practical route to treat lower airway disease in IPF by combining targeted deposition, navigation across mucus and cellular interfaces, and control of drug absorption and retention. Understanding the unique anatomical and biological barriers of fibrotic lungs is essential for rational carrier design.

While preclinical results are encouraging—with multiple nanoparticle systems showing superior antifibrotic efficacy over conventional oral delivery—significant translational gaps remain. No inhaled nanomedicine for IPF has yet reached clinical trials, highlighting the need for continued investment in formulation engineering, device development, and regulatory science.

Priority Research Areas

Mucus-penetrating nanoparticle design: Engineering PEGylated or zwitterionic surface coatings that enable penetration through the thickened IPF mucus barrier while maintaining drug loading efficiency.
Fibroblast-targeted delivery: Developing ligands that selectively target activated myofibroblasts within fibroblastic foci, bypassing the remodeled epithelium to deliver drugs where they are most needed.
Device-formulation co-optimization: Designing nanoparticle formulations together with the inhalation device to ensure consistent aerodynamic performance and preserved nanoparticle integrity during aerosolization.
Combination nanomedicine: Co-loading anti-fibrotic agents (e.g., pirfenidone + siRNA targeting TGF-β) in a single nanoparticle for synergistic therapeutic effects addressing multiple fibrotic pathways simultaneously.
Translational models: Developing ex vivo human IPF lung tissue models and precision-cut lung slices that better predict clinical performance than current rodent bleomycin models.

Why hasn't inhaled nanomedicine for IPF reached clinical trials yet?

Despite promising preclinical results, several practical barriers stand in the way:

Animal model limitations: Most IPF research uses mouse models where fibrosis is induced by a single bleomycin dose—which resolves on its own, unlike human IPF. This makes it hard to predict clinical outcomes.
Scale-up challenges: Manufacturing nanoparticles at pharmaceutical scale with consistent quality is much harder than lab-bench preparation.
Regulatory complexity: Inhaled nanomedicines combine a drug product with a delivery device, requiring dual regulatory approval pathways that add time and cost.
Patient variability: IPF patients have highly variable lung architecture, making consistent drug deposition difficult to achieve across the patient population.

The convergence of advances in nanoparticle engineering, aerosol science, and understanding of IPF pathobiology positions inhaled nanomedicine as a transformative approach for this devastating disease. Success will require interdisciplinary collaboration between materials scientists, pulmonologists, formulation engineers, and regulatory scientists.